News
Public · Published
RBC Capital maintains Eli Lilly at Outperform, raises price target to $1600 from $1500
RBC Capital kept an Outperform rating on Eli Lilly and raised its price target to $1600 from $1500, a 6.7% increase. That target implies 16.5% upside from the October 29 close of $1373.70.
Published:
Updated:
What happened
RBC Capital kept an Outperform rating on Eli Lilly and raised its price target to $1600 from $1500, a 6.7% increase. That target implies 16.5% upside from the October 29 close of $1373.70.
Confirmed
Global impact / market context
A higher price target signals that this analyst expects more room for the share price to rise. Because the target implies 16.5% upside, it may support investor confidence in Eli Lilly shares and draw attention from people deciding where to put money.
Analyst inference
Other recent analyst notes on Eli Lilly show targets from $1316 to $1550, so the new $1600 target sits above that recent range. This points to a more positive view from RBC Capital than several other research firms over the past month.
Analyst inference
What to watch
- Watch whether other analysts change their Eli Lilly price targets following RBC Capital's move to $1600, compared with the recent $1316 to $1550 range. Confirmed
- Investors could compare the new $1600 target with the October 29 closing price of $1373.70 and decide whether the implied 16.5% upside fits their own expectations and risk tolerance. Proposed
- Track Eli Lilly's future results and company updates to see whether actual business performance supports the more positive view behind RBC Capital's higher price target. Analyst inference
Evidence
- Original source link unavailable